Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for Park, Toshiba, and Diasonics. Sardano said his priorities in the position are to expand Elscint's sales force, broaden the company's marketing efforts, and improve the vendor's customer satisfaction levels in the U.S.
Sardano will report to Eliezer Tokman, the Elscint CT veteran who was named to head the company's Americas regional operations in a restructuring announced in November (SCAN 11/12/97). Elscint is moving its global nuclear medicine headquarters to the U.S. as part of the restructuring.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.